Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2005 Feb 4;64(5):699–703. doi: 10.1136/ard.2004.030528

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas

P Geborek 1, A Bladstrom 1, C Turesson 1, A Gulfe 1, I Petersson 1, T Saxne 1, H Olsson 1, L Jacobsson 1
PMCID: PMC1755491  PMID: 15695534

Abstract

Objective: To determine whether TNF blockers increase tumour risk in patients with RA.

Material and methods: The South Swedish Arthritis Treatment Group register (SSATG) comprises over 90% of anti-TNF treated patients with RA in the area. 757 patients treated with etanercept or infliximab included between 1 February 1999 and 31 December 2002 were identified. 800 patients with conventional antirheumatic treatment in a community based cohort served as a comparison cohort. Tumours and deaths were identified in the cancer registry and population census registers. Patients were followed up from initiation of anti-TNF treatment or 1 July 1997 for the comparison group, until death or 31 December 2002.

Results: In the anti-TNF group, 16 tumours (5 lymphomas) were identified in 1603 person-years at risk, and in the comparison group 69 tumours (2 lymphomas) in 3948 person-years. Standardised incidence ratios (SIRs) for total tumour relative risk for the anti-TNF group and the comparison group were 1.1 (95% confidence interval (CI) 0.6 to 1.8) and 1.4 (95% CI 1.1 to 1.8), respectively. The lymphoma relative risk (RR) was 11.5 (95% CI 3.7 to 26.9) and 1.3 (95% CI 0.2 to 4.5), respectively The total tumour RR excluding lymphoma was 0.79 (95% CI 0.4 to 1.42) and 1.39 (95% CI 1.08 to 1.76), respectively. Proportional hazard analysis for lymphomas yielded RR 4.9 (95% CI 0.9 to 26.2) in anti-TNF treated versus untreated patients.

Conclusion: Community based patients with RA treated conventionally had an increased overall tumour risk compared with the background population. A possible additional increased risk for lymphoma associated with TNF blockers was based on few cases and needs confirmation.

Full Text

The Full Text of this article is available as a PDF (77.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. doi: 10.1002/art.1780310302. [DOI] [PubMed] [Google Scholar]
  2. Baecklund E., Ekbom A., Sparén P., Feltelius N., Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ. 1998 Jul 18;317(7152):180–181. doi: 10.1136/bmj.317.7152.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Baecklund Eva, Askling Johan, Rosenquist Richard, Ekbom Anders, Klareskog Lars. Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol. 2004 May;16(3):254–261. doi: 10.1097/00002281-200405000-00014. [DOI] [PubMed] [Google Scholar]
  4. Baecklund Eva, Sundström Christer, Ekbom Anders, Catrina Anca I., Biberfeld Peter, Feltelius Nils, Klareskog Lars. Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. Arthritis Rheum. 2003 Jun;48(6):1543–1550. doi: 10.1002/art.11144. [DOI] [PubMed] [Google Scholar]
  5. Baltus J. A., Boersma J. W., Hartman A. P., Vandenbroucke J. P. The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. Ann Rheum Dis. 1983 Aug;42(4):368–373. doi: 10.1136/ard.42.4.368. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bernstein C. N., Blanchard J. F., Kliewer E., Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001 Feb 15;91(4):854–862. doi: 10.1002/1097-0142(20010215)91:4<854::aid-cncr1073>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  7. Brown S. Lori, Greene Mark H., Gershon Sharon K., Edwards Evelyne T., Braun M. Miles. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002 Dec;46(12):3151–3158. doi: 10.1002/art.10679. [DOI] [PubMed] [Google Scholar]
  8. Carswell E. A., Old L. J., Kassel R. L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666–3670. doi: 10.1073/pnas.72.9.3666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cibere J., Sibley J., Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum. 1997 Sep;40(9):1580–1586. doi: 10.1002/art.1780400906. [DOI] [PubMed] [Google Scholar]
  10. Ekdahl C., Eberhardt K., Andersson S. I., Svensson B. Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire. Scand J Rheumatol. 1988;17(4):263–271. doi: 10.3109/03009748809098795. [DOI] [PubMed] [Google Scholar]
  11. Geborek P., Crnkic M., Petersson I. F., Saxne T., South Swedish Arthritis Treatment Group Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis. 2002 Sep;61(9):793–798. doi: 10.1136/ard.61.9.793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Greenstein A. J., Gennuso R., Sachar D. B., Heimann T., Smith H., Janowitz H. D., Aufses A. H., Jr Extraintestinal cancers in inflammatory bowel disease. Cancer. 1985 Dec 15;56(12):2914–2921. doi: 10.1002/1097-0142(19851215)56:12<2914::aid-cncr2820561232>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  13. Gridley G., McLaughlin J. K., Ekbom A., Klareskog L., Adami H. O., Hacker D. G., Hoover R., Fraumeni J. F., Jr Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst. 1993 Feb 17;85(4):307–311. doi: 10.1093/jnci/85.4.307. [DOI] [PubMed] [Google Scholar]
  14. Hakulinen T., Isomaki H., Knekt P. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am J Med. 1985 Jan 21;78(1A):29–32. doi: 10.1016/0002-9343(85)90242-6. [DOI] [PubMed] [Google Scholar]
  15. Isomäki H. A., Hakulinen T., Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis. 1978;31(11):691–696. doi: 10.1016/0021-9681(78)90071-1. [DOI] [PubMed] [Google Scholar]
  16. Kamel O. W., Holly E. A., van de Rijn M., Lele C., Sah A. A population based, case control study of non-Hodgkin's lymphoma in patients with rheumatoid arthritis. J Rheumatol. 1999 Aug;26(8):1676–1680. [PubMed] [Google Scholar]
  17. Kamel O. W., van de Rijn M., Hanasono M. M., Warnke R. A. Immunosuppression-associated lymphoproliferative disorders in rheumatic patients. Leuk Lymphoma. 1995 Feb;16(5-6):363–368. doi: 10.3109/10428199509054421. [DOI] [PubMed] [Google Scholar]
  18. Katusic S., Beard C. M., Kurland L. T., Weis J. W., Bergstralh E. Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort. Am J Med. 1985 Jan 21;78(1A):50–55. doi: 10.1016/0002-9343(85)90246-3. [DOI] [PubMed] [Google Scholar]
  19. Kauppi M., Pukkala E., Isomäki H. Excess risk of lung cancer in patients with rheumatoid arthritis. J Rheumatol. 1996 Aug;23(8):1484–1485. [PubMed] [Google Scholar]
  20. Kinlen L. J. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med. 1985 Jan 21;78(1A):44–49. doi: 10.1016/0002-9343(85)90245-1. [DOI] [PubMed] [Google Scholar]
  21. Kremer J. M. Is methotrexate oncogenic in patients with rheumatoid arthritis? Semin Arthritis Rheum. 1997 Jun;26(6):785–787. doi: 10.1016/s0049-0172(97)80021-2. [DOI] [PubMed] [Google Scholar]
  22. Matteson E. L., Hickey A. R., Maguire L., Tilson H. H., Urowitz M. B. Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry. Rheumatoid Arthritis Azathioprine Registry Steering Committee. J Rheumatol. 1991 Jun;18(6):809–814. [PubMed] [Google Scholar]
  23. Mellemkjaer L., Linet M. S., Gridley G., Frisch M., Møller H., Olsen J. H. Rheumatoid arthritis and cancer risk. Eur J Cancer. 1996 Sep;32A(10):1753–1757. doi: 10.1016/0959-8049(96)00210-9. [DOI] [PubMed] [Google Scholar]
  24. Ross H. J. The antiproliferative effect of trans-retinoic acid is associated with selective induction of interleukin-1 beta, a cytokine that directly inhibits growth of lung cancer cells. Oncol Res. 1996;8(4):171–178. [PubMed] [Google Scholar]
  25. Saag K. G., Cerhan J. R., Kolluri S., Ohashi K., Hunninghake G. W., Schwartz D. A. Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis. 1997 Aug;56(8):463–469. doi: 10.1136/ard.56.8.463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Silman A. J., Newman J., MacGregor A. J. Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins. Arthritis Rheum. 1996 May;39(5):732–735. doi: 10.1002/art.1780390504. [DOI] [PubMed] [Google Scholar]
  27. Silman A. J., Petrie J., Hazleman B., Evans S. J. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis. 1988 Dec;47(12):988–992. doi: 10.1136/ard.47.12.988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Symmons Deborah P. M., Silman Alan J. Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer. Arthritis Rheum. 2004 Jun;50(6):1703–1706. doi: 10.1002/art.20312. [DOI] [PubMed] [Google Scholar]
  29. Tennis P., Andrews E., Bombardier C., Wang Y., Strand L., West R., Tilson H., Doi P. Record linkage to conduct an epidemiologic study on the association of rheumatoid arthritis and lymphoma in the Province of Saskatchewan, Canada. J Clin Epidemiol. 1993 Jul;46(7):685–695. doi: 10.1016/0895-4356(93)90049-7. [DOI] [PubMed] [Google Scholar]
  30. Thomas E., Brewster D. H., Black R. J., Macfarlane G. J. Risk of malignancy among patients with rheumatic conditions. Int J Cancer. 2000 Nov 1;88(3):497–502. [PubMed] [Google Scholar]
  31. Turesson C., Jacobsson L., Bergström U. Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology (Oxford) 1999 Jul;38(7):668–674. doi: 10.1093/rheumatology/38.7.668. [DOI] [PubMed] [Google Scholar]
  32. Turesson C., O'Fallon W. M., Crowson C. S., Gabriel S. E., Matteson E. L. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis. 2003 Aug;62(8):722–727. doi: 10.1136/ard.62.8.722. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Wolfe Frederick, Michaud Kaleb. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004 Jun;50(6):1740–1751. doi: 10.1002/art.20311. [DOI] [PubMed] [Google Scholar]
  34. Yee C-S, Filer A., Pace A., Douglas K., Situnayake D., Rowe I. F., West Midlands Rheumatology Services and Training Committee The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient study. Rheumatology (Oxford) 2003 Mar 31;42(7):856–859. doi: 10.1093/rheumatology/keg231. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES